Titre:
  • A randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19: the Donated Antibodies Working against nCoV (DAWn-Plasma) trial
Auteur:Devos, Timothy; Geukens, Tatjana; Schauvlieghe, Alexander; Ariën, Kevin K.; Barbezange, Cyril; Cleeren, Myriam; Compernolle, Veerle; Dauby, Nicolas; Desmecht, Daniel; Grimaldi, David; Lambrecht, Bart N.; Luyten, Anne; Maes, Piet; Moutschen, Michel; Romano, Márta; Seyler, Lucie; Toungouz Nevessignsky, Michel; Vandenberghe, Katleen; Van Griensven, Johan; Verbeke, Geert; Vlieghe, Erika; Yombi, Jean Cyr; Liesenborghs, Laurens; Verhamme, Peter; Meyfroidt, Geert
Informations sur la publication:Trials, 21, 1
Statut de publication:Publié, 2020-11-27
Sujet CREF:Médecine pathologie humaine
Langue:Anglais
Identificateurs:urn:issn:1745-6215
info:doi/10.1186/s13063-020-04876-0
info:pii/4876